Skip to content

USANA Health Sciences USNA Core nutritional — Impairment

Similar metrics at other companies

Global Indemnity Group, LLC
 logo
GBLIBelmont Core — Goodwill Impairment
$0
LyondellBasell Industries N.V. logo
LYBOther — Impairments
$0
Colgate-Palmolive logo
CLPet Nutrition — Impairments
$0
Darling Ingredients Inc. logo
DARFeed Ingredients — Asset impairment charges
$8M+1,003%
Fresh Del Monte Produce logo
FDPPrepared foods — Asset impairments
$16.1M
Maravai LifeSciences Holdings, Inc. logo
MRVICorporate — Asset Impairments
$0-100%

Other financials

Income statement

See full
Revenue$250.2M+0.3%
Gross profit$190.8M-3.2%
Operating income$13.9M-11.5%
Net income$7.5M-20.1%
EPS (diluted)$0.41-16.3%

Balance sheet

See full
Cash & equivalents$165.7M-9.2%
Total debt$18.0M+10.8%
Total equity$543.6M+2.6%
Total assets$739.0M-1.0%

Cash flow

See full
Operating cash flow$9.8M-37.0%
CapEx$2.6M-5.6%
Free cash flow$7.1M-43.9%

Valuation

See full
Market cap$363.35M-36.1%
P/E18.1×+7.8×
P/S0.4×-0.3×

Profitability

See full
Gross margin77.6%-3.0pp
Operating margin3.8%-2.7pp
Net margin1.9%-4.4pp
FCF margin5.7%-1.1pp

Returns & leverage

See full
Return on equity3.2%-7.6pp
Debt / equity0.0×
Current ratio2.5×+0.5×

Where this comes from

Reported directly by USANA Health Sciences in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairmentLoss.

The official record: USANA Health Sciences’s 10-K, filed March 16, 2026, on SEC EDGAR. View the filing →

Ask your AI about USANA Health Sciences's core nutritional — impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is USANA Health Sciences's core nutritional — impairment?
USANA Health Sciences (USNA) reported core nutritional — impairment of $6.39M in Q4 2025.
What does core nutritional — impairment mean?
Represents the non-cash charge recognized when the carrying value of assets within the core nutritional segment exceeds their fair value. This indicates a potential decline in the long-term economic viability or market performance of the segment's specific product lines. Investors monitor this to assess the risk of asset overvaluation and management's ability to maintain segment profitability.